Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer

Abstract Background Basal-like breast cancer (BLBC) is a poorly characterised, heterogeneous disease. Patients are diagnosed with aggressive, high-grade tumours and often relapse with chemotherapy resistance. Detailed understanding of the molecular underpinnings of this disease is essential to the d...

Full description

Bibliographic Details
Main Authors: Laura A. Baker, Holly Holliday, Daniel Roden, Christoph Krisp, Sunny Z. Wu, Simon Junankar, Aurelien A. Serandour, Hisham Mohammed, Radhika Nair, Geetha Sankaranarayanan, Andrew M. K. Law, Andrea McFarland, Peter T. Simpson, Sunil Lakhani, Eoin Dodson, Christina Selinger, Lyndal Anderson, Goli Samimi, Neville F. Hacker, Elgene Lim, Christopher J. Ormandy, Matthew J. Naylor, Kaylene Simpson, Iva Nikolic, Sandra O’Toole, Warren Kaplan, Mark J. Cowley, Jason S. Carroll, Mark Molloy, Alexander Swarbrick
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Breast Cancer Research
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13058-020-01306-6
id doaj-afb42d75b5ee42f1b156380d241ca612
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Laura A. Baker
Holly Holliday
Daniel Roden
Christoph Krisp
Sunny Z. Wu
Simon Junankar
Aurelien A. Serandour
Hisham Mohammed
Radhika Nair
Geetha Sankaranarayanan
Andrew M. K. Law
Andrea McFarland
Peter T. Simpson
Sunil Lakhani
Eoin Dodson
Christina Selinger
Lyndal Anderson
Goli Samimi
Neville F. Hacker
Elgene Lim
Christopher J. Ormandy
Matthew J. Naylor
Kaylene Simpson
Iva Nikolic
Sandra O’Toole
Warren Kaplan
Mark J. Cowley
Jason S. Carroll
Mark Molloy
Alexander Swarbrick
spellingShingle Laura A. Baker
Holly Holliday
Daniel Roden
Christoph Krisp
Sunny Z. Wu
Simon Junankar
Aurelien A. Serandour
Hisham Mohammed
Radhika Nair
Geetha Sankaranarayanan
Andrew M. K. Law
Andrea McFarland
Peter T. Simpson
Sunil Lakhani
Eoin Dodson
Christina Selinger
Lyndal Anderson
Goli Samimi
Neville F. Hacker
Elgene Lim
Christopher J. Ormandy
Matthew J. Naylor
Kaylene Simpson
Iva Nikolic
Sandra O’Toole
Warren Kaplan
Mark J. Cowley
Jason S. Carroll
Mark Molloy
Alexander Swarbrick
Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer
Breast Cancer Research
Breast cancer
Transcription factor
Helix-loop-helix
DNA damage
author_facet Laura A. Baker
Holly Holliday
Daniel Roden
Christoph Krisp
Sunny Z. Wu
Simon Junankar
Aurelien A. Serandour
Hisham Mohammed
Radhika Nair
Geetha Sankaranarayanan
Andrew M. K. Law
Andrea McFarland
Peter T. Simpson
Sunil Lakhani
Eoin Dodson
Christina Selinger
Lyndal Anderson
Goli Samimi
Neville F. Hacker
Elgene Lim
Christopher J. Ormandy
Matthew J. Naylor
Kaylene Simpson
Iva Nikolic
Sandra O’Toole
Warren Kaplan
Mark J. Cowley
Jason S. Carroll
Mark Molloy
Alexander Swarbrick
author_sort Laura A. Baker
title Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer
title_short Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer
title_full Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer
title_fullStr Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer
title_full_unstemmed Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer
title_sort proteogenomic analysis of inhibitor of differentiation 4 (id4) in basal-like breast cancer
publisher BMC
series Breast Cancer Research
issn 1465-542X
publishDate 2020-06-01
description Abstract Background Basal-like breast cancer (BLBC) is a poorly characterised, heterogeneous disease. Patients are diagnosed with aggressive, high-grade tumours and often relapse with chemotherapy resistance. Detailed understanding of the molecular underpinnings of this disease is essential to the development of personalised therapeutic strategies. Inhibitor of differentiation 4 (ID4) is a helix-loop-helix transcriptional regulator required for mammary gland development. ID4 is overexpressed in a subset of BLBC patients, associating with a stem-like poor prognosis phenotype, and is necessary for the growth of cell line models of BLBC through unknown mechanisms. Methods Here, we have defined unique molecular insights into the function of ID4 in BLBC and the related disease high-grade serous ovarian cancer (HGSOC), by combining RIME proteomic analysis, ChIP-seq mapping of genomic binding sites and RNA-seq. Results These studies reveal novel interactions with DNA damage response proteins, in particular, mediator of DNA damage checkpoint protein 1 (MDC1). Through MDC1, ID4 interacts with other DNA repair proteins (γH2AX and BRCA1) at fragile chromatin sites. ID4 does not affect transcription at these sites, instead binding to chromatin following DNA damage. Analysis of clinical samples demonstrates that ID4 is amplified and overexpressed at a higher frequency in BRCA1-mutant BLBC compared with sporadic BLBC, providing genetic evidence for an interaction between ID4 and DNA damage repair deficiency. Conclusions These data link the interactions of ID4 with MDC1 to DNA damage repair in the aetiology of BLBC and HGSOC.
topic Breast cancer
Transcription factor
Helix-loop-helix
DNA damage
url http://link.springer.com/article/10.1186/s13058-020-01306-6
work_keys_str_mv AT lauraabaker proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer
AT hollyholliday proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer
AT danielroden proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer
AT christophkrisp proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer
AT sunnyzwu proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer
AT simonjunankar proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer
AT aurelienaserandour proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer
AT hishammohammed proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer
AT radhikanair proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer
AT geethasankaranarayanan proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer
AT andrewmklaw proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer
AT andreamcfarland proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer
AT petertsimpson proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer
AT sunillakhani proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer
AT eoindodson proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer
AT christinaselinger proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer
AT lyndalanderson proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer
AT golisamimi proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer
AT nevillefhacker proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer
AT elgenelim proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer
AT christopherjormandy proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer
AT matthewjnaylor proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer
AT kaylenesimpson proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer
AT ivanikolic proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer
AT sandraotoole proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer
AT warrenkaplan proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer
AT markjcowley proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer
AT jasonscarroll proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer
AT markmolloy proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer
AT alexanderswarbrick proteogenomicanalysisofinhibitorofdifferentiation4id4inbasallikebreastcancer
_version_ 1721559055349055488
spelling doaj-afb42d75b5ee42f1b156380d241ca6122021-04-02T15:47:39ZengBMCBreast Cancer Research1465-542X2020-06-0122111810.1186/s13058-020-01306-6Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancerLaura A. Baker0Holly Holliday1Daniel Roden2Christoph Krisp3Sunny Z. Wu4Simon Junankar5Aurelien A. Serandour6Hisham Mohammed7Radhika Nair8Geetha Sankaranarayanan9Andrew M. K. Law10Andrea McFarland11Peter T. Simpson12Sunil Lakhani13Eoin Dodson14Christina Selinger15Lyndal Anderson16Goli Samimi17Neville F. Hacker18Elgene Lim19Christopher J. Ormandy20Matthew J. Naylor21Kaylene Simpson22Iva Nikolic23Sandra O’Toole24Warren Kaplan25Mark J. Cowley26Jason S. Carroll27Mark Molloy28Alexander Swarbrick29The Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical ResearchThe Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical ResearchThe Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical ResearchAustralian Proteome Analysis Facility (APAF), Department of Chemistry and Biomolecular Sciences, Macquarie UniversityThe Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical ResearchThe Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical ResearchCancer Research UK, The University of Cambridge, Li Ka Shing CentreCancer Research UK, The University of Cambridge, Li Ka Shing CentreRajiv Gandhi Centre for BiotechnologyCancer Research UK, The University of Cambridge, Li Ka Shing CentreThe Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical ResearchThe Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical ResearchCentre for Clinical Research, Faculty of Medicine, The University of QueenslandCentre for Clinical Research, Faculty of Medicine, The University of QueenslandThe Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical ResearchDepartment of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred HospitalDepartment of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred HospitalNational Cancer Institute, National Institutes of HealthSchool of Women’s and Children’s Health, University of New South Wales, and Gynaecological Cancer Centre, Royal Hospital for WomenThe Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical ResearchThe Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical ResearchSchool of Medical Sciences and Bosch Institute, Sydney Medical School, The University of SydneyVictorian Centre for Functional Genomics, Peter MacCallum Cancer CentreVictorian Centre for Functional Genomics, Peter MacCallum Cancer CentreThe Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical ResearchThe Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical ResearchThe Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical ResearchCancer Research UK, The University of Cambridge, Li Ka Shing CentreAustralian Proteome Analysis Facility (APAF), Department of Chemistry and Biomolecular Sciences, Macquarie UniversityThe Kinghorn Cancer Centre and Cancer Research Division, Garvan Institute of Medical ResearchAbstract Background Basal-like breast cancer (BLBC) is a poorly characterised, heterogeneous disease. Patients are diagnosed with aggressive, high-grade tumours and often relapse with chemotherapy resistance. Detailed understanding of the molecular underpinnings of this disease is essential to the development of personalised therapeutic strategies. Inhibitor of differentiation 4 (ID4) is a helix-loop-helix transcriptional regulator required for mammary gland development. ID4 is overexpressed in a subset of BLBC patients, associating with a stem-like poor prognosis phenotype, and is necessary for the growth of cell line models of BLBC through unknown mechanisms. Methods Here, we have defined unique molecular insights into the function of ID4 in BLBC and the related disease high-grade serous ovarian cancer (HGSOC), by combining RIME proteomic analysis, ChIP-seq mapping of genomic binding sites and RNA-seq. Results These studies reveal novel interactions with DNA damage response proteins, in particular, mediator of DNA damage checkpoint protein 1 (MDC1). Through MDC1, ID4 interacts with other DNA repair proteins (γH2AX and BRCA1) at fragile chromatin sites. ID4 does not affect transcription at these sites, instead binding to chromatin following DNA damage. Analysis of clinical samples demonstrates that ID4 is amplified and overexpressed at a higher frequency in BRCA1-mutant BLBC compared with sporadic BLBC, providing genetic evidence for an interaction between ID4 and DNA damage repair deficiency. Conclusions These data link the interactions of ID4 with MDC1 to DNA damage repair in the aetiology of BLBC and HGSOC.http://link.springer.com/article/10.1186/s13058-020-01306-6Breast cancerTranscription factorHelix-loop-helixDNA damage